Australian clinical-stage biotechnology company Vaxxas has expanded its global intellectual property portfolio to 42 patents, supporting its exclusive claim to manufacture and sell its proprietary vaccination technology, the HD-MAP, in the US, Europe, Asia and Australia. …
Vaxxas expands global IP portfolio for exclusive manufacture and sale of needle-free vaccination technology
November 27, 2024 Australian Biotech
Latest Video
Georgia Forrest
New Stories
-
International HTA Collaboration continues as global pricing pressures evolve
January 29, 2026 - - Latest News -
How an Australian Campaign Is tackling the silent epidemic of heart and kidney disease
January 29, 2026 - - Latest News -
ARCS warns workforce gaps threaten returns on clinical trials reform
January 29, 2026 - - Latest News -
AstraZeneca appoints new country president as Ben McDonald transitions to global role
January 29, 2026 - - Latest News -
Why do some appear so uncomfortable with this group of people getting help?
January 29, 2026 - - Latest News -
New digital health reforms to give Australians a more complete medicines history
January 28, 2026 - - Latest News -
Peer-reviewed validation strengthens Paradigm’s osteoarthritis program
January 28, 2026 - - Australian Biotech